Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,28493402,flow rate,"The mobile phase comprised acetonitrile and ammonium formate (10 mm, pH 3.1; 40:60, v/v) pumped at a flow rate of 0.3 mL min-1 .",Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28493402/),[ml] / [min],0.3,8308,DB04876,Vildagliptin
,28493402,recovery,The mean recovery of LIX from mouse plasma was 99.2 ± 0.68%.,Development and validation of HPLC-MS/MS method for the determination of lixivaptan in mouse plasma and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28493402/),%,99.2,8309,DB04876,Vildagliptin
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,98.3,17286,DB04876,Vildagliptin
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,97.4,17287,DB04876,Vildagliptin
,22442826,non-saturable clearance,"Mean parameter estimates (inter-individual coefficient of variation) were: non-saturable clearance 36 l h−1 (25%), central volume of distribution 22 l (37%), half-life of dissociation from DPP-4 1.1 h (94%) and half-life of hydrolysis 6.3 h (81%).",Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22442826/),[l] / [h],36,34221,DB04876,Vildagliptin
,22442826,central volume of distribution,"Mean parameter estimates (inter-individual coefficient of variation) were: non-saturable clearance 36 l h−1 (25%), central volume of distribution 22 l (37%), half-life of dissociation from DPP-4 1.1 h (94%) and half-life of hydrolysis 6.3 h (81%).",Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22442826/),l,22,34222,DB04876,Vildagliptin
,22442826,half-life of dissociation,"Mean parameter estimates (inter-individual coefficient of variation) were: non-saturable clearance 36 l h−1 (25%), central volume of distribution 22 l (37%), half-life of dissociation from DPP-4 1.1 h (94%) and half-life of hydrolysis 6.3 h (81%).",Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22442826/),h,1.1,34223,DB04876,Vildagliptin
,22442826,half-life of hydrolysis,"Mean parameter estimates (inter-individual coefficient of variation) were: non-saturable clearance 36 l h−1 (25%), central volume of distribution 22 l (37%), half-life of dissociation from DPP-4 1.1 h (94%) and half-life of hydrolysis 6.3 h (81%).",Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22442826/),h,6.3,34224,DB04876,Vildagliptin
,18832295,tmax,Vildagliptin was rapidly absorbed (tmax 1.5-2.0 hours) across the dose range of 25 to 200 mg and was quickly eliminated with a terminal elimination half-life (t1/2) of approximately 2 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),h,1.5-2.0,44805,DB04876,Vildagliptin
,18832295,terminal elimination half-life (t1/2),Vildagliptin was rapidly absorbed (tmax 1.5-2.0 hours) across the dose range of 25 to 200 mg and was quickly eliminated with a terminal elimination half-life (t1/2) of approximately 2 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),h,2,44806,DB04876,Vildagliptin
,18832295,accumulation factors,"Consistent with the short t1/2, no accumulation of vildagliptin was observed following the administration of multiple doses (accumulation factors were 1.00-1.05 across the 25- to 200-mg dose range).",Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18832295/),,1.00-1.05,44807,DB04876,Vildagliptin
,18471347,t(max),"Administration of the fixed-dose combination tablet following a high-fat meal had no effect on vildagliptin AUC(0-infinity) (ratio of geometric mean for fed:fasted state, 1.10 [90% CI 1.03, 1.18]), C(max) (ratio of means 0.98 [90% CI 0.85, 1.13]) or median t(max) (2.5 h in fed and fasted states).",Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471347/),h,2.5,50390,DB04876,Vildagliptin
,18471347,t(max),"The rate of absorption of metformin was decreased when given with food, as reflected by the prolonged t(max) (2-4 h) and reduction in C(max) (by 26%), but the extent of absorption was not changed.",Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18471347/),h,2-4,50391,DB04876,Vildagliptin
,21867423,dissociation half-life,Dilution assay indicated a long dissociation half-life (730 min) relative to DPPIV inhibitor vildagliptin.,Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21867423/),min,730,53845,DB04876,Vildagliptin
,17596103,time to reach maximum concentration,Vildagliptin was absorbed rapidly (median time to reach maximum concentration 1 hour) and had a mean terminal elimination half-life ranging from 1.32 to 2.43 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596103/),h,1,71890,DB04876,Vildagliptin
,17596103,terminal elimination half-life,Vildagliptin was absorbed rapidly (median time to reach maximum concentration 1 hour) and had a mean terminal elimination half-life ranging from 1.32 to 2.43 hours.,Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17596103/),h,1.32 to 2.43,71891,DB04876,Vildagliptin
,20735236,T(max),"Following a single oral dose of 25, 50, and 100 mg x kg(-1), T(max) values were from 1.25 to 1.84 h, CL/F values were around 100 l h(-1) kg(-1).","Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735236/),h,1.25 to 1.84,95323,DB04876,Vildagliptin
,20735236,CL/F,"Following a single oral dose of 25, 50, and 100 mg x kg(-1), T(max) values were from 1.25 to 1.84 h, CL/F values were around 100 l h(-1) kg(-1).","Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735236/),[l] / [h·kg],100,95324,DB04876,Vildagliptin
,20735236,C(max),"In the dose range, C(max) values (63.9-296 μg x l(-1)) and AUC(0-∞)values (260-1214 μg x h x l(-1)) were proportional to the doses.","Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735236/),[μg] / [l],63.9-296,95325,DB04876,Vildagliptin
,20735236,AUC(0-∞),"In the dose range, C(max) values (63.9-296 μg x l(-1)) and AUC(0-∞)values (260-1214 μg x h x l(-1)) were proportional to the doses.","Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20735236/),[h·μg] / [l],260-1214,95326,DB04876,Vildagliptin
,28406239,IC50,The IC50 of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),nM,12,109775,DB04876,Vildagliptin
,28406239,IC50,The IC50 of CMD-05 on DPP-IV inhibitory activity was approximately 12 nM while vildagliptin was 3.5 nM in vitro.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),nM,3.5,109776,DB04876,Vildagliptin
,28406239,half-life,"After oral administration, CMD-05 reached peak concentration at 30 min with half-life of 288 minutes and the inhibitory rate of DPP-IV greater than 50% lasted for 15 h.","CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),min,288,109777,DB04876,Vildagliptin
,28406239,maximum tolerance dose,CMD-05 had a lower cytotoxicity than vildagliptin in vitro and its maximum tolerance dose in mice is beyond 2000 mg/kg.,"CMD-05, a novel promising clinical anti-diabetic drug candidate, in vivo and vitro studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28406239/),[mg] / [kg],2000,109778,DB04876,Vildagliptin
,22339447,absolute bioavailability,"Following oral administration, vildagliptin is rapidly and well absorbed with an absolute bioavailability of 85%.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),%,85,128972,DB04876,Vildagliptin
,22339447,volume of distribution,"Vildagliptin is minimally bound to plasma proteins (9.3%) and, on the basis of a volume of distribution of 71 L, it is considered to distribute extensively into extravascular spaces.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),l,71,128973,DB04876,Vildagliptin
,22339447,Renal clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],13,128974,DB04876,Vildagliptin
,22339447,total body clearance,Renal clearance of vildagliptin (13 L/h) accounts for 33% of the total body clearance after intravenous administration (41 L/h).,Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[l] / [h],41,128975,DB04876,Vildagliptin
,22339447,IC(50)),"Vildagliptin is a potent inhibitor of the DPP-4 enzyme, with a concentration required to achieve 50% DPP-4 inhibition (IC(50)) of 4.5 nmol/L in patients with T2DM.",Clinical pharmacokinetics and pharmacodynamics of vildagliptin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22339447/),[nM] / [l],4.5,128976,DB04876,Vildagliptin
,17713976,absolute oral bioavailability,Both noncompartmental analysis and population pharmacokinetic modelling estimated the absolute oral bioavailability of vildagliptin to be 85%.,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),%,85,148705,DB04876,Vildagliptin
,17713976,Renal clearance,Renal clearance (13 L/h) was approximately one-third of the total systemic clearance (41 L/h).,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),[l] / [h],13,148706,DB04876,Vildagliptin
,17713976,total systemic clearance,Renal clearance (13 L/h) was approximately one-third of the total systemic clearance (41 L/h).,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),[l] / [h],41,148707,DB04876,Vildagliptin
,17713976,lag-times,Modelling based on the population approach identified two absorption sites with lag-times of 0.225 and 2.46 hours.,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),h,0.225,148708,DB04876,Vildagliptin
,17713976,lag-times,Modelling based on the population approach identified two absorption sites with lag-times of 0.225 and 2.46 hours.,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),h,2.46,148709,DB04876,Vildagliptin
,17713976,Clearance,Clearance was 24% greater in males (44.6 L/h) than in females (36.1 L/h).,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),[l] / [h],44.6,148710,DB04876,Vildagliptin
,17713976,Clearance,Clearance was 24% greater in males (44.6 L/h) than in females (36.1 L/h).,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),[l] / [h],36.1,148711,DB04876,Vildagliptin
,17713976,absolute bioavailability,Vildagliptin is rapidly and well absorbed with an estimated absolute bioavailability of 85%.,"The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713976/),%,85,148712,DB04876,Vildagliptin
,24771661,retention time,"The injection volume necessary was only 10 μL, and retention time was 4.60 min.",Validation of LC-MS/MS method applied to evaluation of free tissue concentrations of vildagliptin in diabetic rats by microdialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24771661/),min,4.60,151893,DB04876,Vildagliptin
,16027230,minimum effective dose (MED),A single oral dose of vildagliptin in Zucker rats produced a rapid and dose-related inhibition of DPP-4: the minimum effective dose (MED) was 0.3 mg/kg.,Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027230/),[mg] / [kg],0.3,158988,DB04876,Vildagliptin
,17442688,t(max),The t(max) for parent drug was observed between 0.5 and 1.5 hours postdose.,Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17442688/),h,0.5 and 1.5,168109,DB04876,Vildagliptin
,26932305,t(max),"The rate of absorption of metformin decreased when administered under fed condition, as reflected by a prolonged t(max) (3 hours in fasted state vs. 4 hours in fed state) and decrease in C(max) by 26%, however, the extent of absorption (AUC(last)) was similar to that in the fasted state.",Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26932305/),h,3,186719,DB04876,Vildagliptin
,26932305,t(max),"The rate of absorption of metformin decreased when administered under fed condition, as reflected by a prolonged t(max) (3 hours in fasted state vs. 4 hours in fed state) and decrease in C(max) by 26%, however, the extent of absorption (AUC(last)) was similar to that in the fasted state.",Bioequivalence and food effect assessment for vildagliptin/metformin fixed-dose combination tablets relative to free combination of vildagliptin and metformin in Japanese healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26932305/),h,4,186720,DB04876,Vildagliptin
,22456294,tmax,Vildagliptin absorption appeared slower when administered 30 min before rather than immediately before meals (tmax absolute range: 1.00 - 2.00 h vs. 0.33 - 1.58 h).,Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456294/),h,1.00 - 2.00,186859,DB04876,Vildagliptin
,22456294,tmax,Vildagliptin absorption appeared slower when administered 30 min before rather than immediately before meals (tmax absolute range: 1.00 - 2.00 h vs. 0.33 - 1.58 h).,Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456294/),h,0.33 - 1.58,186860,DB04876,Vildagliptin
,22456294,AUE0-4 h,"-5.8 mg/dl; adjusted AUE0-4 h, -67.0 vs. -51.0 mg×h/dl).",Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456294/),[h·mg] / [dl],-,186861,DB04876,Vildagliptin
,22456294,AUE0-4 h,"-5.8 mg/dl; adjusted AUE0-4 h, -67.0 vs. -51.0 mg×h/dl).",Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456294/),[h·mg] / [dl],67.0,186862,DB04876,Vildagliptin
,22456294,AUE0-4 h,"-5.8 mg/dl; adjusted AUE0-4 h, -67.0 vs. -51.0 mg×h/dl).",Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456294/),[h·mg] / [dl],51.0,186863,DB04876,Vildagliptin
,19074975,fraction of drug absorbed,The fraction of drug absorbed was calculated to be at least 85.4%.,"Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074975/),%,85.4,236076,DB04876,Vildagliptin
,19074975,terminal half-life,The terminal half-life of vildagliptin was 2.8 h.,"Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074975/),h,2.8,236077,DB04876,Vildagliptin
,19074976,bioavailability,Moderate to high bioavailability was observed in both species (45-100%).,"Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),%,45-100,264236,DB04876,Vildagliptin
,19074976,distribution,"The distribution and elimination half-lives of vildagliptin were short: 0.57 h [82% of area under the plasma drug concentration-time curve (AUC)] and 8.8 h in the rat and 0.05 and 0.89 h (87% of AUC) in the dog, respectively.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),h,0.57,264237,DB04876,Vildagliptin
,19074976,distribution,"The distribution and elimination half-lives of vildagliptin were short: 0.57 h [82% of area under the plasma drug concentration-time curve (AUC)] and 8.8 h in the rat and 0.05 and 0.89 h (87% of AUC) in the dog, respectively.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),h,0.05,264238,DB04876,Vildagliptin
,19074976,elimination half-lives,"The distribution and elimination half-lives of vildagliptin were short: 0.57 h [82% of area under the plasma drug concentration-time curve (AUC)] and 8.8 h in the rat and 0.05 and 0.89 h (87% of AUC) in the dog, respectively.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),h,8.8,264239,DB04876,Vildagliptin
,19074976,elimination half-lives,"The distribution and elimination half-lives of vildagliptin were short: 0.57 h [82% of area under the plasma drug concentration-time curve (AUC)] and 8.8 h in the rat and 0.05 and 0.89 h (87% of AUC) in the dog, respectively.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),h,0.89,264240,DB04876,Vildagliptin
,19074976,volume of distribution,"The volume of distribution was 1.6 and 8.6 l/kg in dogs and rats, respectively, indicating moderate to high tissue distribution.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),[l] / [kg],1.6,264241,DB04876,Vildagliptin
,19074976,volume of distribution,"The volume of distribution was 1.6 and 8.6 l/kg in dogs and rats, respectively, indicating moderate to high tissue distribution.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),[l] / [kg],8.6,264242,DB04876,Vildagliptin
,19074976,plasma clearance,The plasma clearance of vildagliptin was relatively high for the rat (2.9 l/h/kg) and dog (1.3 l/h/kg) compared with their hepatic blood flow.,"Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),[l] / [h·kg],2.9,264243,DB04876,Vildagliptin
,19074976,plasma clearance,The plasma clearance of vildagliptin was relatively high for the rat (2.9 l/h/kg) and dog (1.3 l/h/kg) compared with their hepatic blood flow.,"Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),[l] / [h·kg],1.3,264244,DB04876,Vildagliptin
,19074976,urinary excretion,"After intravenous dosing, urinary excretion of radioactivity (47.6-72.4%) was the major route of elimination for rats and dogs as 18.9 to 21.3% of the dose was excreted into urine as unchanged parent drug.","Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19074976/),%,47.6-72.4,264245,DB04876,Vildagliptin
